PROCEPT BioRobotics Corporation (PRCT) Stock Analysis

Q: What is the PRCT stock price target?

Take-profit $28.52 (+1.5% upside). Prior stop was $26.14.

Q: What are the risks of investing in PRCT?

Target reached (-5.8% upside); Quality below floor (3.2 < 4.0); Target reached (-5.8% upside); Quality below floor (3.2 < 4.0).

Q: Is PRCT overvalued or undervalued?

PROCEPT BioRobotics Corporation trades at a P/E of N/A (forward -29.9). TrendMatrix value score: 5.3/10. Overall verdict: Sell.

Q: What do analysts say about PRCT?

21 analysts cover PRCT with a consensus score of 3.9/5. Average price target: $30.

Recovery setup

SellModerate ConfidenceUpdated 3 min ago (May 20, 2026, 4:21 PM ET)

Healthcare · Medical Devices

Sell if holding. Engine safety override at $28.11: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 11%; Below-average business quality; Below long-term trend.

$28.11+1.5% A.UpsideScore 4.9/10#35 of 40 Medical Devices

QualityF-score6 / 9FCF yield-2.93%

Stop $26.14Target $28.52(resistance)A.R:R -0.4:1

Analyst target$30.44+8.3%9 analysts

$28.52our TP

$28.11price

$30.44mean

$20

$37

Passes 6/10 gates (positive momentum, no SEC red flags, news events none recent, earnings proximity 82d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity and death cross (50MA < 200MA). Suitability: aggressive.

Recent Developments — PROCEPT BioRobotics Corporation

Latest news

Piper Sandler Reiterates Overweight on PROCEPT BioRobotics, Raises Price Target to $35 — benzinga Apr 30, 2026 positive
12 Health Care Stocks Moving In Thursday's Pre-Market Session — benzinga Apr 30, 2026 neutral
12 Health Care Stocks Moving In Wednesday's After-Market Session — benzinga Apr 29, 2026 neutral
PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $396.674M Est — benzinga Apr 29, 2026 neutral
PROCEPT BioRobotics Q1 EPS $(0.56), Inline, Sales $83.132M Beat $80.506M Estimate — benzinga Apr 29, 2026 positive

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards

No bull case signals

Risks

Target reached (-5.8% upside)

Quality below floor (3.2 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-29.9

Mkt Cap$1.5B

EV/EBITDA-12.8

Profit Mgn-31.8%

ROE-27.8%

Rev Growth20.2%

Beta0.83

DividendNone

Rating analysts21

Quality Signals

Piotroski F6/9MoatNarrow

Options Flow

P/C0.10bullish

IV67%elevated

Max Pain$18-37.7% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.315%0.79

Quality3.215%0.48

Growth7.615%1.14

Momentum4.510%0.45

Sentiment6.210%0.62

Insider Activity6.310%0.63

Peer Rank2.910%0.29

Technical Setup0.65%0.03

Risk Profile5.45%0.27

Catalyst3.95%0.20

Overall (Σ contributions)4.90

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

52w Position

0.0

Bollinger

0.5

Support Resistance

1.3

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

1.0

Value Rank

2.5

Growth Rank

8.0

Unprofitable operations — net margin -31.8%. Quality floor flags this regardless of sector context.static

Roe

0.0

Roa

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Current Ratio

6.3

Piotroski F

6.7

Moat

7.2

Gross Margin

8.8

Cash-burning: FCF -13% of revenue

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg

0.0

Erm

5.0

Earnings Timing

5.0

Earnings History

5.6

GatesA.R:R -0.4=NEGATIVEINSIDER 0.67%=EXTREMEDeath cross (50MA < 200MA)Momentum 4.5<5.5 (soft — BUY_NOW allowed but watch)Momentum 4.5>=4.5No SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 82d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Aggressive

RSI

67 · Neutral

↑ 20D MA↑ 50D MA↓ 200D MADEATH CROSSSupport $21.28Resistance $29.10

Price Targets

$26

$29

A.Upside+1.5%

A.R:R-0.4:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Target reached (-5.8% upside)

! Quality below floor (3.2 < 4.0)

! Negative risk/reward — downside exceeds upside

Earnings

2/4 beats

Next Earnings2026-08-10 (82d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is PRCT stock a buy right now?

Sell if holding. Engine safety override at $28.11: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 11%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 67. Prior stop was $26.14. Score 4.9/10, moderate confidence.

What is the PRCT stock price target?

Take-profit target: $28.52 (+1.5% upside). Prior stop was $26.14. Stop-loss: $26.14.

What are the risks of investing in PRCT?

Target reached (-5.8% upside); Quality below floor (3.2 < 4.0).

Is PRCT overvalued or undervalued?

PROCEPT BioRobotics Corporation trades at a P/E of N/A (forward -29.9). TrendMatrix value score: 5.3/10. Verdict: Sell.

What do analysts say about PRCT?

21 analysts cover PRCT with a consensus score of 3.9/5. Average price target: $30.

What does PROCEPT BioRobotics Corporation do?PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the...

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.